60 Degrees Pharmaceuticals (NASDAQ:SXTP – Get Free Report) and VBI Vaccines (NASDAQ:VBIV – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, risk and institutional ownership.
Insider and Institutional Ownership
8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are held by institutional investors. 10.3% of 60 Degrees Pharmaceuticals shares are held by company insiders. Comparatively, 10.4% of VBI Vaccines shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Recommendations
This is a breakdown of current ratings and target prices for 60 Degrees Pharmaceuticals and VBI Vaccines, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
60 Degrees Pharmaceuticals | 0 | 1 | 1 | 0 | 2.50 |
VBI Vaccines | 0 | 0 | 0 | 0 | N/A |
Earnings and Valuation
This table compares 60 Degrees Pharmaceuticals and VBI Vaccines’ top-line revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
60 Degrees Pharmaceuticals | $250,000.00 | 11.89 | -$3.77 million | ($1.04) | -1.62 |
VBI Vaccines | $9.41 million | 0.05 | -$92.84 million | N/A | N/A |
60 Degrees Pharmaceuticals has higher earnings, but lower revenue than VBI Vaccines.
Profitability
This table compares 60 Degrees Pharmaceuticals and VBI Vaccines’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
60 Degrees Pharmaceuticals | N/A | N/A | -98.31% |
VBI Vaccines | -881.79% | -525.42% | -45.87% |
Summary
60 Degrees Pharmaceuticals beats VBI Vaccines on 6 of the 10 factors compared between the two stocks.
About 60 Degrees Pharmaceuticals
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
About VBI Vaccines
VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
Receive News & Ratings for 60 Degrees Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.